|
- Theodore G. Krontiris, M.D., Ph.D., Director
- Richard Jove, Ph.D., Deputy Director
- Smita Bhatia, M.D., M.PH., Associate Director for Population Research
- Robert Figlin, M.D., Associate Director for Clinical Research
- Joyce C. Niland, Ph.D., Associate Director for Information Sciences
- John J. Rossi, Ph.D., Associate Director for Laboratory Research
- Yun Yen, M.D., Ph.D., Associate Director for Translational Research
Theodore G. Krontiris, M.D., Ph.D.
Director, City of Hope Comprehensive Cancer Center
Executive Vice President for Medical and Scientific Affairs
Theodore Krontiris, M.D., Ph.D., joined City of Hope (COH) in 1996 as chair of the newly established Division of Molecular Medicine. Prior to coming to COH, Dr. Krontiris held several medical and teaching positions at Tufts University School of Medicine and Tufts New England Medical Center Hospitals, where he was founding director of the Graduate Program in Genetics at Sackler Graduate School. Dr. Krontiris also served as an instructor at Harvard Medical School.
Dr. Krontiris received his medical degree and PhD from Albert Einstein College of Medicine in Bronx, New York, and an AB degree in Mathematics from the University of Chicago. He is a member of the American Society of Human Genetics, the American Society of Microbiology, the American Society of Hematology, and the American Society of Clinical Oncology. He has served in numerous advisory panels for the National Institutes of Health and the National Cancer Institute, and currently serves on the editorial board and as associate editor for The Journal of Clinical Oncology and Current Molecular Medicine, respectively.
Dr. Krontiris' research interest is genetic susceptibility to commonly occuring cancers. He leads a national study of sibling pairs affected with breast, colon, lung and prostate cancer in collaboration with the Eastern Cooperative Oncology Group.
As executive vice president for Medical and Scientific Affairs, Dr. Krontiris' executive responsibilities include medical and scientific programmatic development, integration and oversight. In addition, he continues to maintain responsibilities as a professor and the Chairmanship of the Clinical and Scientific Executive Team (CSET).
Richard Jove, Ph.D.
Deputy Director, City of Hope Comprehensive Cancer Center
Richard Jove, Ph.D., joined City of Hope in October, 2005 as deputy director of City of Hope’s National Cancer Institute-designated Comprehensive Cancer Center; chair and professor of the Division of Molecular Medicine; and co-leader of the Developmental Cancer Therapeutics program.
As deputy director, Jove plays a key role in leading a major cancer center-wide effort to develop the next generation of more effective and less toxic drugs for treatment of cancer. He is a pioneer in identifying STAT proteins as new molecular targets for cancer therapy.
Prior to joining City of Hope, Jove served as director of the Molecular Oncology Program and associate director of Basic Research at the H. Lee Moffitt Cancer Center and Research Institute. Earlier in his career, he was a tenured faculty member at the University of Michigan Medical School, where he also served as director of Molecular Oncology. Jove earned his Ph.D. in molecular biology from Columbia University and received postdoctoral training in cancer research at Rockefeller University.
Jove has published 135 original research articles in peer-reviewed journals and is the recipient of numerous honors during his career, including the John S. Newberry Prize in Biology at Columbia University; Damon Runyon-Walter Winchell Cancer Fund Postdoctoral Fellowship at Rockefeller University; American Cancer Society Junior Faculty Research Award at the University of Michigan; and 2003 Scientist of the Year Award by the H. Lee Moffitt Cancer Center.
Smita Bhatia, M.D., M.P.H.
Associate Director for Population Research, City of Hope Comprehensive Cancer Center
Smita Bhatia, M.D., M.P.H., was named associate director of City of Hope’s comprehensive cancer center and professor and chair of a new Division of Population Sciences in January, 2006. She also leads the Cancer Prevention and Control Program, and is a staff physician in the Division of Pediatrics. Dr. Bhatia previously served as director, Epidemiology and Outcomes Research within the Division of Pediatrics at City of Hope.
Bhatia’s research focuses on long-term complications among survivors of adult and pediatric cancer. She is currently conducting a comprehensive, multi-institution study of survivors of bone marrow transplantation. As chair of the Children’s Oncology Group Late Effects Committee, Bhatia is responsible for coordinating late effects research occurring within the national cooperative group. She is also responsible for a national centralized database of key adverse events among children treated with Children’s Oncology Group therapeutic protocols
Bhatia received her M.P.H. in Epidemiology from the University of Minnesota, Minneapolis in 1994, and her MD in Pediatrics and M.P.H. Epidemiology from All India Institute of Medical Sciences in New Delhi, India. She has received numerous awards and honors including the Brigid Leventhal Merit Award and a Young Investigator Award, both from the American Society of Clinical Oncology; and the Leukemia and Lymphoma Society Scholar in Clinical Research Award in 2001.
Robert Figlin, M.D.
Associate Director for Clinical Research, City of Hope Comprehensive Cancer Center
Robert Figlin, M.D., has been appointed associate director for Clinical Research for City of Hope, chair of the Medical Oncology and Therapeutics Research division, and Arthur and Rosalie Kaplan Professor of Medical Oncology. A nationally recognized leader in genitourinary and thoracic oncology, Figlin will focus his research on renal cell carcinoma and thoracic malignancies. He will establish and direct a Kidney Cancer Program at City of Hope, and will continue to serve as the co-principal investigator of the UCLA Lung Cancer Specialized Program of Research Excellence (SPORE), which he will bring to City of Hope as part of the Southern California Lung Cancer Consortium.
Prior to joining City of Hope, Figlin served as the Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology and professor of medicine and urology in the divisions of Hematology/Oncology and Urologic Oncology at the David Geffen School of Medicine at UCLA. Figlin joined the UCLA faculty in 1982 as assistant professor of medicine in the Division of Hematology/Oncology and was appointed co-director of the Jonsson Comprehensive Cancer Center’s oncology program in 1993. He also held the post of medical director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as program director of Solid Tumor Development Therapeutics within the comprehensive cancer center.
Figlin received his medical degree from the Medical College of Pennsylvania. He completed his residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology at UCLA’s Geffen School of Medicine. He is board certified in medical oncology and internal medicine. Figlin’s studies have appeared in Clinical Cancer Research, the Journal of Clinical Oncology and the Journal of Urology, among others. He serves as editor for the peer–reviewed Kidney Cancer Journal.
Joyce C. Niland, Ph.D.
Associate Director for Information Sciences, City of Hope Comprehensive Cancer Center
Joyce C. Niland, Ph.D. has served as City of Hope's director of Biostatistics since 1988. A full professor with a joint appointment in the Beckman Research Institute, she also chairs City of Hope's Division of Information Services and holds an adjunct faculty appointment in Preventive Medicine in the Keck School of Medicine at the University of Southern California.
For more than 25 years, she has been at the leading edge of her field, serving on numerous review panels for the National Institutes of Health, as an external advisor to several cancer centers, associate editor for two major journals, and co-author of a textbook on information systems for clinical research. A frequent author and lecturer, she is also director of the Data Coordinating Centers for the National Comprehensive Cancer Network Outcomes Research Project, and for the national Islet Cell Resources for transplantation of islet cells in Type 1 Diabetes.
In addition, Dr. Niland is principal investigator of an IAIMS implementation grant funded by the NLM; chair of the Clinical Trials Working Group for the American Medical Informatics Association; and co-chair of a Data Standards Subcommittee for the American Association of Cancer Institutes. Among Dr. Niland’s many honors, she was elected to become a fellow of the American Statistical Association, based on her contributions in the fields of Biostatistics and Biomedical Informatics.
Dr. Niland received her bachelor's degree in Human Biology from Stanford University, master's degrees in Physical Therapy and in Biometry from the University of Southern California (USC), and her doctorate in Biometry from USC.
John J. Rossi, Ph.D.
Associate Director for Laboratory Research, City of Hope Comprehensive Cancer Center
John J. Rossi, PhD came to City of Hope (COH) in 1980 as an assistant research scientist in the Department of Molecular Genetics. He was promoted to chairman of the Division of Biology in 1992. In 1993, COH bestowed its highest honor upon him by naming him to its Gallery of Medical and Scientific Achievement for his pioneering work at the molecular level in the battle against AIDS and other major diseases. In 1998 Dr. Rossi was appointed as the Dean of the City of Hope Graduate School of Biological Sciences.
Dr. Rossi is a world-renowned expert in ribozymes (molecular scissors). Dr. Rossi’s major contributions to science have been through understanding the processing and metabolism of RNA inside the cell. Ribozymes, also known as catalytic RNA and "molecular scissors", are molecules that can break down nucleic acid inside a cell, thus they can be used to cut out "bad" genetic information and splice in "good" material. One of his most notable projects is in the area of ribozyme research in AIDS. He led the research team that first suggested applying ribozymes to treat HIV. His research in molecular genetics and microbiology has earned eight patents and has served as the basis for more than 120 scientific papers.
Born and raised in Washington D.C., Dr. Rossi received his bachelor’s degree from the University of New Hampshire and earned his doctorate at the University of Connecticut. He completed four years of post PhD training at Brown University in Providence, Rhode Island before coming to COH.
Yun Yen, M.D., Ph.D.
Associate Director for Translational Research, City of Hope Comprehensive Cancer Center
Yun Yen, MD, PhD, currently oversees the Clinical and Experimental Therapeutics Program of the City of Hope Comprehensive Cancer Center.
Dr. Yen received his medical degree from Taipei Medical College in Taiwan and his PhD in Pathology and Cell Biology from Thomas Jefferson University, Philadelphia, Pennsylvania. Following residency training at St. Luke's Hospital, Temple University, Dr. Yen completed a fellowship in the Department of Internal Medicine, Hematology and Bone Marrow Transplantation and Oncology Section at Yale University School of Medicine. Subsequently, he joined City of Hope in 1993 as a staff physician. He is currently a professor in Medical Oncology and the Graduate School of Biological Sciences, as well as chief of Biochemical Pharmacology in the Division of Medical Oncology & Therapeutics Research.
Among Dr. Yen’s grant awards are several from the National Institutes of Health, including a prestigious predoctoral fellowship training grant while at Thomas Jefferson University and a K12 training grant while at City of Hope. In addition, he has been awarded U. S. Army Breast Cancer and Prostate Cancer grants, and the National Cancer Institute’s Cancer Therapy Evaluation Program has designated his laboratory the ribonucleotide reductase Real-Time PCR Reference Laboratory.
Dr. Yen holds membership in numerous professional organizations, including the American Association for the Advancement of Science, American Society of Clinical Oncology, Sigma-Xi Scientific Association, and Academy of Science New York. He has published more than 140 abstracts and peer-reviewed journal articles, and he serves as an ad hoc reviewer/referee for several journals and on the editorial board of the Journal of Clinical Colorectal Cancer.
As a highly experienced clinician, clinical investigator and basic scientist, Dr. Yen’s research interests focus on several markers of hepatocellular cancer, as well as investigational therapies for advanced malignancy.
|